anonymous
Guest
anonymous
Guest
Bingo, Hanson knows how to manipulate so shareholders are clueless, then when there’s no more he can do they sell and make a very large bonus. Just watch.
How did the directed rebate work out for Surgical? Recognizing full value of capital, selling it off, but keeping the lease payments. Only works when capital sales increase, but once it slows then look out. Negative revenue and then the revenue Reclass happens. Surgical - thrived when SYK on FDA hold/recall. Once they were back, new capital dried up, but claw back payments due. GR model. Only a matter of time for Rosa. If that’s not enough, let’s borrow the CRM practice of bulk buys to mask revenue shortfalls. It’s the medical device equivalent of crack.